Alpha Metallurgical Resources, Inc.

Fundamentals6.0
Price Action6.0
News Sentiment5.0
AI Rating
6.0

Key Drivers

  • Strong liquidity
  • Low leverage
  • Negative operating profit

AI
AI Summary

6.0

AMR should be revalued not as a pure commodity-timing bet but as a balance-sheet-led, execution-sensitive investment: its strong cash/low-debt cushion supports optionality, but the investment case now hinges on successful Kingston Wildcat ramp, disciplined capex that converts EBITDA into stable positive FCF, and at least partial stabilization of met-coal realizations. Track near-term contracted volumes/prices, capex split (development vs. maintenance), and quarterly FCF conversion—if Kingston hits guidance with contained capex and contracts hold, upside is material; if not, downside risk from pricing or impairments is significant.

BalanceSheet
ContractRisk
Execution‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Strong liquidity
  • Low leverage
  • Negative operating profit

AMR shows strong liquidity and very low debt but is impaired by recurring operating losses and capital intensity despite positive FY cash flow.

Liquidity
OperatingLoss

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Short-term uptrend
  • Above 21‑day MA
  • Resistance near $200

AMR has traded higher over the last month, closing above its short-term moving average with positive momentum but facing resistance near $198–$200 that could trigger a pullback if not cleared.

Bullish
WatchResistance
Support Level: $162–$170
Resistance Level: $198–$200

Price jumped from $176.73 to $193.69 over the last month, indicating rapid short-term strength

Sentiment & News

5.0

Key News Insights:

  • Q4 earnings weakness
  • Mixed institutional flows
  • Peer valuation focus

Alpha Metallurgical reported Q4 net loss and weak adjusted EBITDA, drew a Strong Sell from Zacks, saw mixed institutional trades but an insider buy, and faced peer-comparison scrutiny through Feb–Mar 2026.

caution
insiderbuy

The weak results and sell rating likely pressure the stock near term, though the insider purchase and peer comparisons may temper downside if markets reassess valuation